Lead Product(s) : Bucillamine,Acetylcysteine
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Revive Updates Bucillamine for Nerve Agent Exposure with Canada’s Defence Research
Details : Bucillamine is a potent antioxidant and anti-inflammatory, small molecule drug candidate. It is being evaluated for the treatment of nerve agent induced brain injury seizure.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Bucillamine,Acetylcysteine
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Argenx
Deal Size : Undisclosed
Deal Type : Collaboration
Raya Therapeutic Announces Early-Stage R&D Collaboration with Argenx
Details : The collaboration aims to focus on testing combinations of Raya's pipeline of targeted small molecules with a potentially complementary product from argenx.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 07, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Argenx
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Bucillamine
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Defence R&D Canada
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to evaluate Bucillamine, a significantly more effective antioxidant than n-acetylcysteine, as a potential treatment for nerve agent exposure.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 17, 2023
Lead Product(s) : Bucillamine
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Defence R&D Canada
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Cyclosporine
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Arctoris
Deal Size : Undisclosed
Deal Type : Partnership
Details : Cyclica’s platform and capabilities in combination with the biological assay development of Arctoris will enable us to yield meaningful results and advance research development for patients suffering from Alzheimers and other neurodegenerative diseases...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
March 23, 2022
Lead Product(s) : Cyclosporine
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Arctoris
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cannabinoid
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oral administration of cannabinoids is the most convenient route for non-invasive drug delivery. Avicanna intends to conduct further pre-clinical studies in the coming months in order to formalize this provisional application and will incorporate the tec...
Product Name : re+PLAY
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2021
Lead Product(s) : Cannabinoid
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells, a process that mimics neuronal degeneration for treatment of neurodegenerative disorders.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 10, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabinoid
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The PCT application demonstrate cannabinoid compound inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection also can be used to promote neurite outgrowth, signifying the potential to enhance neuronal function.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2021
Lead Product(s) : Cannabinoid
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dihydrohonokiol-B
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BetterLife Files Patent Protection on Dihydrohonokiol-B for Treatment of Anxiolytic Use Disorder
Details : BetterLife has filed patent protection on the newest compound to enter its pipeline, dihydrohonokiol-B (“TD-010”). Specifically, BetterLife has filed for patent protection for the use of TD-010 as a treatment for sedative, hypnotic, or anxiolytic us...
Product Name : TD-010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2021
Lead Product(s) : Dihydrohonokiol-B
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabinoid
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Solarvest BioEnergy
Deal Size : Undisclosed
Deal Type : Agreement
FSD Pharma and Solarvest Enhance Commitment to CBD Research Project
Details : Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subordinate voting shares to Solarvest, which will enable Solarvest to fund the CBD Research Project.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 02, 2020
Lead Product(s) : Cannabinoid
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Solarvest BioEnergy
Deal Size : Undisclosed
Deal Type : Agreement